Table 3.
Impact of 18F-FDG-PET/CT on intended clinical management stratified generally as “treatment” vs “non-treatment” (N = 43)
| Indication for PET/CT | All Patients | |||||
|---|---|---|---|---|---|---|
| Management plan | Pre-PET/CT | Post-PET/CT | Diagnosis | Staging | Recurrence | |
| No. of scans per indication (%) | 2 (4.7%) | 20 (46.5%) | 21 (48.8%) | 43 (100%) | ||
| Treatmenta | Treatmenta | - | 6 (14%) | 1 (2.3%) | 7 (16.3%) | |
| Non-treatmentb | Non-treatmentb | - | 3 (7.0%) | 7 (16.3%) | 10 (23.3%) | |
| Non-treatmentb | Treatmenta | - | 10 (23.3%) | 7 (16.3%) | 17 (39.5%) | |
| Treatmenta | Non-treatmentb | 2 (4.7%) | 1 (2.3%) | 6 (14.0%) | 9 (20.9%) | |
| Change in clinical patient management | 2 (100%) | 11 (55%) | 13 (61.9%) | 26 (60.5%) | ||
| 95% confidence interval | 32.0–78.0% | 40.5–83.3% | 45.5–75.5% | |||
a
Treatment: surgical resection, liver transplantation, systemic chemotherapy, TACE, radiation therapy, and combinations.
b
Non-treatment: watchful waiting, and additional diagnostic tests (e.g., imaging, biopsy).